(Q33325817)

25 July 2017

1 reference

title

Rimonabant: new data and emerging experience (English)

1 reference

25 July 2017

Suzanne M Wright

1

1 reference

25 July 2017

Carolien Dikkers

series ordinal

2

1 reference

25 July 2017

Louis J Aronne

series ordinal

3

1 reference

25 July 2017

1 February 2008

1 reference

Current Atherosclerosis Reports

25 July 2017

1 reference

25 July 2017

10

1 reference

25 July 2017

71-78

1 reference

25 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-008-0011-5

25 July 2017

0 references

cites work

The endocannabinoid system: physiology and pharmacology.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-008-0011-5

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-008-0011-5

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

21 January 2018

1 reference

12 December 2020

Prevalence of overweight and obesity in the United States, 1999-2004

1 reference

12 December 2020

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

12 December 2020

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

12 December 2020

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

12 December 2020

Extent of overweight among US children and adolescents from 1971 to 2000

1 reference

12 December 2020

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

Molecular characterization of a peripheral receptor for cannabinoids

1 reference

12 December 2020

The endocannabinoid system as a target for therapeutic drugs.

1 reference

12 December 2020

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

1 reference

12 December 2020

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

12 December 2020

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

1 reference

12 December 2020

Actual Causes of Death in the United States, 2000

1 reference

12 December 2020

1 reference

12 December 2020

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

12 December 2020

Endocannabinoid control of food intake and energy balance

1 reference

12 December 2020

Plasma adiponectin levels and risk of myocardial infarction in men.

1 reference

12 December 2020

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

12 December 2020

The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals

1 reference

12 December 2020

Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity

1 reference

12 December 2020

Activation of the peripheral endocannabinoid system in human obesity

1 reference

12 December 2020

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

1 reference

12 December 2020

10.1007/S11883-008-0011-5

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference